Mydecine Innovations Group Public Offering led by Canaccord Genuity Corp.

Written By SykoActive

As an emerging BioPharma and life sciences company, Mydecine is currently researching and developing alternative natural medicines and constructing a drug pipeline for the psychedelic industry.

images (40).jpg

Mydecine received 34,500,000 units of the company for an issue price of $0.50 per unit which makes the aggregated proceeds to the company at $17,250,000. Mydecine operates a cGMP certified lab in Canada and a state-of-the-art mycology lab in Denver Colorado focusing on genetic research for vertically integrated commercial cultivation of non-psychoactive medicinal mushrooms. Mydecine plans to use net proceeds of the offering to invest in additional clinical trials and expand its intellectual property portfolio. Mydecine is also aggressively pursuing continued collaborations and initiatives to generate additional working capital. Joshua Barch, CEO of Mydecine states, "We are excited about the closing of this financing. We greatly appreciate the interest and support from our investor base. This offering further strengthens Mydecines balance sheet and positions the company for continued growth in 2021." Warrants are expected to be listed for trading on the Canadian securities exchange on Tuesday, February 16, 2021.

SykoActive

Graham Krutch, also known as 'Gram Kracker,' is the founder and CEO of SykoActive Non-Profit Association, boasting over two decades of experience in the industry of medicinal plants and psychedelic substances. His expertise extends from cultivation to patient consultation, primarily focusing on cannabis and psilocybin, alongside notable advancements in the hemp and CBD sector.

Under Graham's guidance, SykoActive investigates and advocates for the therapeutic uses of psychedelic plant medicines. He is committed to informing the public about secure alternative treatments and tackling the worldwide mental health dilemma.

Beyond his involvement in the psychedelic realm, Graham possesses a varied skill set in event marketing and product management. His efforts have been instrumental in the prosperity of leading convenience stores, and he shines in team leadership, strategic planning, and project management. As a fervent proponent of Applied AI Science and proficient in AI research and technological tools, he adeptly merges a customer-centric approach with an acute awareness of time constraints.

https://www.sykoactive.com
Previous

Pharmadrug Files for FDA Orphan Drug Destination for DMT Treatments
Next

Will Vermont Bring Back House Bill H.878?